Trial Profile
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 06 Aug 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.